Agios製藥 AGIO 深 滬
已收盤 08-01 16:00:00 美东时间
35.00
-2.220
-5.96%
華盛通- 最 高38.43
- 今 開37.27
- 成交量 235.11万股
- 最 低 34.32
- 昨 收 37.22
- 總市值 20.27亿
- 52周最高 62.58
- 市盈率 靜 3.01
- 換手率 0.00%
- 52周最低 23.415
- 委 比 62.86%
- 總股本 5791.52万
- 歷史最高 138.85
- 量 比 3.07
- 振 幅 11.04%
- 歷史最低 15.77
- 每 手 1
- 風險率 8.39%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Agios Pharmaceuticals Q2 EPS $(1.93) Misses $(1.77) Estimate, Sales $12.455M Beat $9.537M Estimate
Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.93) per share which missed the analyst consensus estimate of $(1.77) by 8.73 percent. This is a 14.2 percent decrease over losses of $(1.69) per share
07-31 18:32
Earnings Scheduled For July 31, 2025
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (...
07-31 16:32
Agios Reports Second Quarter 2025 Financial Results and Provides Business Update
Agios Pharmaceuticals reported second-quarter 2025 financial results, highlighting $12.5 million in net revenue for PYRUKYND® (mitapivat) and $1.3 billion in cash reserves. The company made progress on regulatory filings, including the sNDA for PYRUKYND in thalassemia with an FDA PDUFA date of September 7, 2025, and launched Phase 2 trials for tebapivat in sickle cell disease. R&D expenses increased to $91.9 million, reflecting advancements in th...
07-31 10:30
Here are the major earnings before the open Thursday
Major earnings expected before the bell on Thursday include: AbbVie (OTC:ABBY) Bristol-Myers Squibb Company (BMY) Mastercard Incorporated (MA) CVS Health Corporation (CVS) Shell plc (SHEL) Other earni...
07-31 06:00
美股大行评级 | 微软获上调目标价最高至570美元；摩根大通维持网易"超配"评级，目标价升至140美元
今日重点评级关注：Leerink Partners：维持Celcuity"跑赢大市"评级，目标价从28美元升至60美元；Macquarie：维持Churchill Downs"跑赢大市"评级，目标价从150美元升至155美元
07-29 09:30
美股大行评级 | 丰业银行上调Meta目标价从525美元升至675美元；恩智浦获"超配"评级，目标价从190美元升至220美元
今日重点评级关注：瑞杰金融：维持Antero Resources Corp."强烈买入"评级，目标价从57美元升至58美元；美银证券：维持和黄医药"买入"评级，目标价从27美元升至28美元
07-23 09:42
B of A Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $51
B of A Securities analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $52 to $51.
07-23 00:15
Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET
<p>Agios Pharmaceuticals has announced a conference call and live webcast on July 31, 2025, at 8:00 a.m. ET to present its second quarter 2025 financial results and business highlights. The webcast will be available on the company’s website under the "Events & Presentations" tab, with a replay accessible approximately two hours after the event. Agios is a leader in PK activation and develops therapies for rare diseases, including treatments for P...
07-14 11:00
Agios Appoints Dr. Jay Backstrom to Board of Directors
Agios Pharmaceuticals announced the appointment of Jay Backstrom, M.D., M.P.H., to its Board of Directors. Dr. Backstrom brings extensive experience in advancing clinical programs across therapeutic areas, including rare diseases, and has held leadership roles at companies like Scholar Rock, Acceleron Pharma, and Celgene. His addition is seen as strategic as Agios focuses on maximizing the potential of its PK activator, PYRUKYND, and advancing it...
07-08 11:00
Agios Pharma (AGIO) Gets a Hold from J.P. Morgan
In a report released today, Tessa Romero from J.P. Morgan maintained a Hold rat...
06-25 19:27
